



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12Q 1/68, C12P 19/34, C07H 21/04</p>	A1	<p>(11) International Publication Number: WO 99/31275</p> <p>(43) International Publication Date: 24 June 1999 (24.06.99)</p>
<p>(21) International Application Number: PCT/US98/26515</p> <p>(22) International Filing Date: 14 December 1998 (14.12.98)</p> <p>(30) Priority Data: 08/990,436 15 December 1997 (15.12.97) US</p> <p>(71) Applicant (for all designated States except US): NEXSTAR PHARMACEUTICALS, INC. [US/US]; Suite 200, 2860 Wildemess Place, Boulder, CO 80301 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): GOLD, Larry [-/US]; 1033 5th Street, Boulder, CO 80302 (US). DROLET, Daniel [-/US]; 6844 Bugle Court, Boulder, CO 80301 (US). ZICHI, Dominic, A. [-/US]; 2200 Kalmia Avenue, Boulder, CO 80304 (US). JAYASENA, Sumedha [-/US]; 5875 North Orchard Creek Circle, Boulder, CO 80301 (US). CREIGHTON, Steve [-/US]; 9799 East Jewell Avenue, #204, Denver, CO 80231 (US). GILL, Stanley [-/US]; 1004 Grant Place, Boulder, CO 80302 (US).</p> <p>(74) Agents: SWANSON, Barry, J. et al.; Swanson & Bratschun, L.L.C., Suite 200, 8400 E. Prentice Avenue, Englewood, CO 80111 (US).</p>		
<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p>		
<p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>		
<p>(54) Title: NUCLEIC ACID LIGAND DIAGNOSTIC BIOCHIP</p> <p>(57) Abstract</p> <p>A nucleic acid ligand "biochip" is disclosed, consisting of a solid support to which one or more specific nucleic acid ligands is attached in a spatially defined manner. Each nucleic acid ligand binds specifically and avidly to a particular target molecule contained within a test mixture, such as a bodily fluid. The target molecules include, but are not limited to, proteins (cellular, viral, bacterial, etc.) hormones, sugars, metabolic byproducts, cofactor, and intermediates, drugs, and toxins. Contacting the test mixture with the biochip leads to the binding of a target molecule to its cognate nucleic acid ligand. Binding of target to the nucleic acid ligand results in a detectable change at each specific location on the biochip. The detectable change can include, but is not limited to, a change in fluorescence, or a change in a physical parameter, such as electrical conductance or refractive index, at each location on the biochip. The biochip will then be read by a device, such as a fluorescence scanner or a surface plasmon resonance detector, that can measure the magnitude of the change at each location on the biochip. The location of the change reveals what target molecule has been detected, and the magnitude of the change indicates how much of it is present. The combination of these two pieces of information will yield diagnostic and prognostic medical information when signal patterns are compared with those obtained from bodily fluids of individuals with diagnosed disorders. In principle, the biochip could be used to test any chemically complex mixture provided that nucleic acid ligands to components suspected of being present in the mixture are attached to the biochip. Thus, the nucleic acid ligand biochip will have a wider use in environmental testing, etc.</p>		
<p style="text-align: center;">4x4 Array</p> <p style="text-align: center;">1. Incubation with test mixture 2. Detection of binding</p> <p style="text-align: center;">Expanded view of two sites</p> <p style="text-align: center;">Normal Binding Pattern</p> <p style="text-align: center;">Disease 1 Binding Pattern Site A lower; site P higher</p> <p style="text-align: center;">Disease 2 Binding Pattern Site F lower; site K higher</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NUCLEIC ACID LIGAND DIAGNOSTIC BIOCHIP

Field of the Invention

The invention is directed to methods for the detection of target molecules in test solutions, particularly medically relevant molecules contained in bodily fluids. The methods described herein use specific nucleic acid ligands attached to solid supports at spatially discrete locations. The invention provides methods for detecting the binding of target molecules to nucleic acid ligands, and methods for using arrays of nucleic acid ligands in diagnostic medical applications.

Background of the Invention

A method for the *in vitro* evolution of nucleic acid molecules with highly specific binding to target molecules has been developed. This method, Systematic Evolution of Ligands by Exponential Enrichment, termed the SELEX process, is described in United States Patent Application Serial No. 07/536,428, entitled "Systematic Evolution of Ligands by Exponential Enrichment," now abandoned, United States Patent Application Serial No. 07/714,131, filed June 10, 1991, entitled "Nucleic Acid Ligands," now United States Patent No. 5,475,096, United States Patent Application Serial No. 07/931,473, filed August 17, 1992, entitled "Methods for Identifying Nucleic Acid Ligands," now United States Patent No. 5,270,163 (see also WO 91/19813), each of which is herein specifically incorporated by reference. Each of these applications, collectively referred to herein as the SELEX patent applications, describes a fundamentally novel method for making a nucleic acid ligand to any desired target molecule.

The SELEX method involves selection from a mixture of candidate oligonucleotides and step-wise iterations of binding, partitioning and amplification, using the same general selection scheme, to achieve virtually any desired criterion of binding affinity and selectivity.

Starting from a mixture of nucleic acids, preferably comprising a segment of randomized sequence, the SELEX method includes steps of contacting the mixture with the target under conditions favorable for binding, partitioning unbound nucleic acids from those nucleic acids which have bound specifically to target molecules, dissociating the nucleic acid-target complexes, amplifying the nucleic acids dissociated from the nucleic acid-target complexes to yield a ligand-enriched mixture of nucleic acids, then reiterating the steps of binding,

partitioning, dissociating and amplifying through as many cycles as desired to yield highly specific, high affinity nucleic acid ligands to the target molecule.

The SELEX method encompasses the identification of high-affinity nucleic acid ligands containing modified nucleotides conferring improved characteristics on the ligand, such as improved *in vivo* stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions. SELEX-identified nucleic acid ligands containing modified nucleotides are described in United States Patent Application Serial No. 08/117,991, filed September 8, 1993, entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides," that describes oligonucleotide containing nucleotide derivatives chemically modified at the 5- and 2'-positions of pyrimidines. United States Patent Application Serial No. 08/134,028, *supra*, describes highly specific nucleic acid ligands containing one or more nucleotides modified with 2'-amino (2'-NH₂), 2'-fluoro (2'-F), and/or 2'-O-methyl (2'-OMe). United States Patent Application Serial No. 08/264,029, filed June 22, 1994, entitled "Novel Method of Preparation of Known and Novel 2' Modified Nucleosides by Intramolecular Nucleophilic Displacement," describes oligonucleotide containing various 2'-modified pyrimidines.

Given the remarkable ability of nucleic acid ligands to be generated against many different target molecules, it would be desirable to have methods for using said ligands as a diagnostic tool. In particular, it would be desirable to attach a plurality of different nucleic acid ligands to a microfabricated solid support (a "biochip"), and then assay the binding to said ligands of target molecules in a bodily fluid. The subject application provides such methods.

Summary of the Invention

Methods are provided in the instant invention for obtaining diagnostic and prognostic nucleic acid ligands, attaching said ligands to a biochip, and detecting binding of target molecules in a bodily fluid to said biochip-bound nucleic acid ligands. In one embodiment of the instant invention, one or more nucleic acid ligands are chosen that bind to molecules known to be diagnostic or prognostic of a disease; these ligands are then attached to the biochip. Particular methods for attaching the nucleic acid ligands to the biochip are described below in the section entitled "Fabrication of the Nucleic Acid Biochip." The biochip may comprise either (i) nucleic acid ligands selected against a single target molecule; or more

preferably, (ii) nucleic acid ligands selected against multiple target molecules. In the subject invention, the level of target molecule binding to nucleic acid ligands at defined spatial locations will be determined using bodily fluid from individuals known to have the disease for which that target molecule is known to be prognostic or diagnostic, and also using bodily fluid from healthy individuals. Bodily fluid from an individual seeking a prognostic report can then be assayed using the biochip, and comparison of the three sets of data will yield prognostic or diagnostic information for that individual.

In another embodiment, the specific nucleic acid ligands attached to the biochip bind specifically to all or a large number of components of blood plasma, or other bodily fluids, of a healthy individual. The pattern and level of binding of these ligands to their targets will then be determined by the methods disclosed below for healthy individuals, and also for individuals diagnosed with various medical conditions. A computer database of biochip binding data will then be established, with each disease giving rise to a unique "signature" binding pattern. Bodily fluids from individuals desiring a prognostic or diagnostic report will then be contacted with the biochip, and the binding pattern obtained compared with the reference database.

In a related embodiment, the attached nucleic acid ligands will bind specifically to all or a large number of components of the blood plasma, or other bodily fluid, of an individual known to be suffering from a particular disease. Once the pattern and level of target molecule binding to this biochip has been determined for the individual suffering from the disease, this biochip can be used to screen individuals known to be at risk of developing this disease. This embodiment will be useful for diseases in which the target molecules are not found in the bodily fluid of healthy individuals, and the target molecules themselves are not yet identified (e.g., for viral, bacterial or parasitic infections where the causative agent has not yet been characterized at the molecular level).

In all the methods described in this invention, it is not necessary to know what each nucleic acid ligand is binding. The preceding two embodiments are particularly preferred, as they will allow for the early diagnosis of diseases for which there are no currently known assays, and for which diagnosis traditionally depends on the manifestation of overt disease symptoms. It will then be possible to identify the nucleic acid ligands that are binding target molecules of relevance, and thereby identify those target molecules. These embodiments will greatly expedite research into disease, and will provide many new target molecules that can

be used in directed diagnostic and drug discovery programs. Furthermore, the nucleic acid ligands identified on the biochip that bind to these target molecules may themselves have potential for use as therapeutic agents.

In the most preferred embodiment, the biochip contains both types of nucleic acid
5 ligands described in the previous two embodiments. Such a biochip will be able to detect or predict diseases where the diagnostic or prognostic criterion is (i) a change in the concentration of molecule(s) normally found in bodily fluid; and/or (ii) the presence of a molecule not normally found in a bodily fluid of a healthy individual, e.g., a viral protein. Figure 1 shows the use of such a biochip. For the sake of clarity, only a simple 4x4 array is
10 illustrated; typical embodiments may use arrays that are 100x100 or greater.

Brief Description of The Drawings

FIGURE 1 shows the use of a patterned array of nucleic acid ligands. Contacting the biochip with a test mixture results in a binding pattern that can be used to diagnose or predict
15 disease.

FIGURE 2 depicts a mechanism for detection in which an oligonucleotide, complementary in sequence to all or part of the nucleic acid ligand, is displaced from the nucleic acid ligand by binding of the target molecule.
20

FIGURE 3 illustrates a mechanism for detection in which a nucleic acid ligand is bound to the biochip via its interaction with an oligonucleotide, which oligonucleotide is covalently attached to the biochip, and has a sequence complementary to all or part of the sequence of the nucleic acid ligand.
25

FIGURE 4 shows a mechanism for detection in which a small molecule is bound to the surface of the biochip, and the nucleic acid ligands incorporate a binding site for this molecule.

FIGURE 5 depicts a mechanism for detection of target molecule binding in which a
30 nucleic acid ligand containing an additional binding site for a small molecule is immobilized on a biochip.

FIGURE 6 depicts a detection system that uses a cascade of nucleic acid hybridization.

5 Detailed Description of The Invention

Contents

- I. Glossary
- II. Obtaining Nucleic Acid Ligands For Use on a Biochip
- III. Fabrication of the Nucleic Acid Ligand Biochip
- 10 IV. Detection of Target Molecule Binding to Nucleic Acid Ligand Using Fluorescence Techniques
 - A. Generic Detection Techniques
 - B. Detection Using an Oligonucleotide with Sequence Complementary to the Nucleic Acid Ligand
 - 15 C. Incorporation of Small Molecule Binding Sites into Nucleic Acid Ligands to Facilitate Detection of Target Molecule Binding
 - D. Detection Through a Hybridization Cascade
 - E. Direct Binding of Target Molecules to Spectroscopically Detectable Nucleic Acid Ligands
 - 20 F. Detection of Changes in Double-Helicity Accompanying Target Binding
 - G. Detection through the use of Interferometry
 - H. Detection of Covalently-Bound Target Molecules
- V. Detection of Target Molecule Binding Through Methods That Do Not Involve Fluorescence
 - 25 A. Chemical Field Effect Transistors
 - B. Detection Through Surface Plasmon Resonance
 - C. Detection Through the Use of Mass Spectroscopy
 - D. Detection Through Atomic Force Microscopy (AFM) and Scanning-Tunneling Microscopy (STM)
- 30 VI. Examples

I. Glossary

The following terms are intended to have the following general meanings as they are used herein:

1. "SELEX" methodology refers to the selection of nucleic acid ligands which
5 interact with a target in a desirable manner, for example binding to a protein, with
amplification of those selected nucleic acids as described in detail above and in the SELEX
patent applications. Iterative cycling of the selection/amplification steps allows selection of
one or a small number of nucleic acids which interact most strongly with the target from a
pool which contains a very large number of nucleic acids. Cycling of the
10 selection/amplification procedure is continued until a selected goal is achieved.
2. "SELEX target" or "target molecule" or "target" refers herein to any
compound upon which a nucleic acid can act in a predetermined desirable manner. A SELEX
target molecule can be a protein, peptide, nucleic acid, carbohydrate, lipid, polysaccharide,
glycoprotein, hormone, receptor, antigen, antibody, virus, pathogen, toxic substance,
15 substrate, metabolite, transition state analog, cofactor, inhibitor, drug, dye, nutrient, growth
factor, cell, tissue, etc., without limitation. Virtually any chemical or biological effector
would be a suitable SELEX target. Molecules of any size can serve as SELEX targets. A
target can also be modified in certain ways to enhance the likelihood of an interaction
between the target and the nucleic acid.
- 20 3. "Tissue target" or "tissue" refers herein to a certain subset of the SELEX
targets described above. According to this definition, tissues are macromolecule in a
heterogeneous environment. As used herein, tissue refers to a single cell type, a collection of
cell types, an aggregate of cells, or an aggregate of macromolecules. This differs from
simpler SELEX targets which are typically isolated soluble molecules, such as proteins. In
25 the preferred embodiment, tissues are insoluble macromolecules which are orders of
magnitude larger than simpler SELEX targets. Tissues are complex targets made up of
numerous macromolecules, each macromolecule having numerous potential epitopes. The
different macromolecules which comprise the numerous epitopes can be proteins, lipids,
carbohydrates, etc., or combinations thereof. Tissues are generally a physical array of
30 macromolecules that can be either fluid or rigid, both in terms of structure and composition.
Extracellular matrix is an example of a more rigid tissue, both structurally and
compositionally, while a membrane bilayer is more fluid in structure and composition.

Tissues are generally not soluble and remain in solid phase, and thus partitioning can be accomplished relatively easily. Tissue includes, but is not limited to, an aggregate of cells usually of a particular kind together with their intercellular substance that form one of the structural materials commonly used to denote the general cellular fabric of a given organ, e.g., kidney tissue, brain tissue. The four general classes of tissues are epithelial tissue, connective tissue, nerve tissue and muscle tissue.

Examples of tissues which fall within this definition include, but are not limited to, heterogeneous aggregates of macromolecule such as fibrin clots which are acellular; homogeneous or heterogeneous aggregates of cells; higher ordered structures containing cells which have a specific function, such as organs, tumors, lymph nodes, arteries, etc.; and individual cells. Tissues or cells can be in their natural environment, isolated, or in tissue culture. The tissue can be intact or modified. The modification can include numerous changes such as transformation, transfection, activation, and substructure isolation, e.g., cell membranes, cell nuclei, cell organelles, etc.

Sources of the tissue, cell or subcellular structures can be obtained from prokaryotes as well as eukaryotes. This includes human, animal, plant, bacterial, fungal and viral structures.

4. "Nucleic acid" means either DNA, RNA, single-stranded or double-stranded and any chemical modifications thereof. Modifications include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interaction, and fluxionality to the individual nucleic acid bases or to the nucleic acid as a whole. Such modifications include, but are not limited to, modified bases such as 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at cytosine exocyclic amines, substitution of 5-bromo-uracil; backbone modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3' and 5' modifications such as capping. Modifications that occur after each round of amplification are also compatible with this invention. Post-amplification modifications can be reversibly or irreversibly added after each round of amplification. Virtually any modification of the nucleic acid is contemplated by this invention.

5. "Nucleic acid test mixture" or "nucleic acid candidate mixture" refers herein to a mixture of nucleic acids of differing, randomized sequence. The source of a "nucleic acid

test mixture" can be from naturally-occurring nucleic acids or fragments thereof, chemically synthesized nucleic acids, enzymatically synthesized nucleic acids or nucleic acids made by a combination of the foregoing techniques. In a preferred embodiment, each nucleic acid has fixed sequences surrounding a randomized region to facilitate the amplification process. The length of the randomized section of the nucleic acid is generally between 8 and 250 nucleotides, preferably between 8 and 60 nucleotides.

6. "Nucleic acid ligand" refers herein to a nucleic acid which has been isolated from the nucleic acid candidate mixture that acts on a target in a desirable manner. Examples of actions on a target in a desirable manner include, but are not limited to binding of the target, catalytically changing the target, reacting with the target in a way which modifies/alters the target or the functional activity of the target, covalently attaching to the target as in a suicide inhibitor, facilitating the reaction between the target and another molecule. In most, but not all, instances this desirable manner is binding to the target. In the most preferred embodiment, a nucleic acid ligand is a non-naturally occurring nucleic acid sequence having a specific binding affinity for a target molecule, such target molecule being a three dimensional chemical structure other than a polynucleotide that binds to said nucleic acid ligand through a mechanism which predominantly depends on Watson/Crick base pairing or triple helix binding, wherein said nucleic acid ligand is not a nucleic acid having the known physiological function of being bound by the target molecule. Nucleic acid ligand includes nucleic acid sequences that are substantially homologous to the nucleic acid ligands actually isolated by the SELEX procedures. By substantially homologous it is meant a degree of primary sequence homology in excess of 70%, most preferably in excess of 80%. In the past it has been shown that various nucleic acid ligands to a specific target with little or no primary homology may have substantially the same ability to bind the target. For these reasons, this invention also includes nucleic acid ligands that have substantially the same ability to bind a target as the nucleic acid ligands identified by the SELEX process. Substantially the same ability to bind a target means that the affinity is within a few orders of magnitude of the affinity of the ligands described herein. It is well within the skill of those of ordinary skill in the art to determine whether a given sequence -- substantially homologous to those specifically described herein -- has substantially the same ability to bind a target.

7. "Bodily fluid" refers herein to a mixture of macromolecules obtained from an organism. This includes, but is not limited to, blood plasma, urine, semen, saliva, lymph

fluid, meningeal fluid, amniotic fluid, glandular fluid, and cerebrospinal fluid. This also includes experimentally separated fractions of all of the preceding. "Bodily fluid" also includes solutions or mixtures containing homogenized solid material, such as feces, tissues, and biopsy samples.

5 8. "Test mixture" refers herein to any sample that contains a plurality of molecules, the identity of at least some of which can be detected using a nucleic acid ligand biochip. This includes, but is not limited to, bodily fluids as defined above, and any sample for environmental and toxicology testing such as contaminated water and industrial effluent.

 9. "Biochip" is any microfabricated solid surface to which molecules may be
10 attached through either covalent or non-covalent bonds. This includes, but is not limited to, Langmuir-Bodgett films, functionalized glass, germanium, silicon, PTFE, polystyrene, gallium arsenide, gold, and silver. Any other material known in the art that is capable of having functional groups such as amino, carboxyl, thiol or hydroxyl incorporated on its surface, is contemplated. This includes planar surfaces, and also spherical surfaces.

15

II. Obtaining Nucleic Acid Ligands For Use on a Biochip

 The basic SELEX method has been modified to achieve a number of specific objectives. For example, United States Patent Application Serial No. 08/123,935, filed September 17, 1993, abandoned in favor of United States Patent Application Serial No.
20 08/443,959, filed May 18, 1995, entitled "Photoselection of Nucleic Acid Ligands," describes a SELEX based method for selecting nucleic acid ligands containing photoreactive groups capable of binding and/or photocrosslinking to and/or photoinactivating a target molecule. United States Patent Application Serial No. 08/134,028, filed October 7, 1993, abandoned in favor of United States Patent Application Serial No. 08/443,957, filed May 18, 1995, now
25 United States Patent No. 5,580,737, entitled "High-Affinity Nucleic Acid Ligands That Discriminate Between Theophylline and Caffeine," describes a method for identifying highly specific nucleic acid ligands able to discriminate between closely related molecules, termed Counter-SELEX. United States Patent Application Serial No. 08/143,564, filed October 25, 1993, abandoned in favor of United States Patent Application Serial No. 08/461,069, filed
30 June 5, 1995, now United States Patent No. 5,567,588, entitled "Systematic Evolution of Ligands by EXponential Enrichment: Solution SELEX," describes a SELEX-based method which achieves highly efficient partitioning between oligonucleotide having high and low

affinity for a target molecule. United States Patent Application Serial No. 08/442,062, filed May 16 1995, entitled "Methods of Producing Nucleic Acid Ligands," now United States Patent No. 5,595,877, describes methods for obtaining improved nucleic acid ligands after SELEX has been performed. United States Patent Application Serial No. 08/400,440, filed 5 March 8, 1995, now United States Patent No. 5,705,337, entitled "Systematic Evolution of Ligands by EXponential Enrichment: Chemi-SELEX," describes methods for covalently linking a ligand to its target. Of particular note to the instant application, United States Patent Application Serial No. 08/434,425, filed May 3, 1995, now United States Patent No. 5,789,157, entitled "Tissue SELEX," describes methods for identifying and preparing nucleic 10 acid ligands against an entire tissue, wherein tissue is defined as a single cell type, a collection of cell types, an aggregate of cells or an aggregate of macromolecules. Examples of candidate tissues include tumors and blood plasma. These methods are also disclosed in great detail in United States Patent Application Serial Nos. 08/434,425, 08/437,667, 08/434,001, 08/433,585, 08/906,955, 08/433,124, and 08/433,126.

15 The SELEX method encompasses combining selected oligonucleotide with other selected oligonucleotide and non-oligonucleotide functional units as described in United States Patent Application Serial No. 08/284,063, filed August 2, 1994, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Chimeric SELEX," now United States Patent No. 5,637,459, and United States Patent Application Serial No. 08/234,997, filed April 20 28, 1994, now United States Patent No. 5,683,867, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Blended SELEX," respectively. These applications allow the combination of the broad array of shapes and other properties, and the efficient amplification and replication properties of oligonucleotide with the desirable properties of other molecules. Each of the above described patent applications which describe modifications of the basic 25 SELEX procedure are specifically incorporated by reference herein in their entirety. Any variation of the SELEX method that allows for the incorporation of a detectable group (such as a fluorescent chemical, or a group such as digoxigenin that is recognized by an antibody), an affinity group (such as biotin), a reactive group (such as a photoreactive group or a chemical group that permits attachment of the ligand to a biochip surface), or of the binding 30 site sequence of another SELEX target is also contemplated in the subject invention.

In a preferred embodiment, the SELEX procedure is carried out in the presence of blood plasma in order ultimately to obtain nucleic acid ligands that bind the target molecule

specifically without the possibility that they cross react with other molecules in plasma.

Some examples of nucleic acid ligands that have utility in the biochip include, but are not limited to, ligands against HIV-1 tat protein (United States Patent Nos. 5,527,894 and 5,637,461), HIV-1 gag (United States Patent No. 5,726,017), HIV-1 integrase (United States Patent No. 5,587,468), HIV-1 nucleocapsid components (United States Patent Nos. 5,654,151 and 5,635,615) HIV-1 reverse transcriptase (United States Patent Nos. 5,496,938 and 5,503,978), thrombin (United States Patent Nos. 5,476,766 and 5,543,293), basic fibroblast growth factor (United States Patent Nos. 5,459,015 and 5,639,868), vascular endothelial growth factor (United States Patent No. 5,811,533), insulin receptor antibodies (United States Patent Application Serial No. 08/248,632, now abandoned), the tachykinin substance P (United States Patent No. 5,648,214 and 5,637,682), immunoglobulin E (United States Patent Nos. 5,629,155 and 5,686,592), secretory phospholipase A₂ (United States Patent No. 5,622,828), TGFβ (United States Patent Nos. 5,731,144 and 5,731,424), platelet derived growth factor (United States Patent No. 5,668,264, United States Patent No. 5,723,594 and World Patent No. WO 96/38579), human keratinocyte growth factor (World Patent No. WO 96/38579, United States Patent No. 5,846,713), chorionic gonadotropin (United States Patent Nos. 5,837,456 and 5,849,890), lectins (United States Patent No. 5,780,228 and United States Patent Application Serial Nos. 08/477,829 and 08/472,256), cytokines (United States Patent Application Serial Nos. 08/477,527 and 08/481,710), lupus antibodies (United States Patent Application Serial No. 08/520,932, now abandoned), and complement system proteins (United States Patent Application Serial No. 08/595,335, now abandoned).

As described in the SELEX patent applications, it is possible to create nucleic acid ligands with constant and random sequence regions. In a particularly preferred embodiment, nucleic acid ligands will be synthesized that have a common short sequence (seq. A) located at a predetermined position. The initial candidate mixture of nucleic acids will then be contacted with a solid support, preferably a column, containing an immobilized nucleic acid (seq. A') complementary in sequence to the common short sequence on each ligand. The pool of ligands will then bind to the column through complementary base pairing between A and A'. A mixture containing the target molecule(s) will then be passed over the column, and ligands that are displaced from the column will be collected. The displacement of these ligands indicates that the binding of the target molecule alters the conformation of the ligand in such a manner that the common short sequence is no longer able to bind to its

complementary sequence. In a related embodiment, the initial candidate mixture of nucleic acid ligands will be contacted with the target molecule, and binding will be allowed to occur in solution phase. The nucleic acid ligands will then be contacted with the column described above. Nucleic acid ligands that have bound target in such a way that sequence A is not able
5 to hybridize to column-bound sequence A' will pass through the column, and can be collected. The nucleic acid ligands obtained in these two embodiments will be used in the biochip as described in detail below in the section entitled "Detection of Target Molecule Binding to Nucleic Acid Ligand Using Fluorescence Techniques."

One of the most powerful aspects of the present invention is the ability to identify an
10 extremely large number of nucleic acid ligands that recognize correspondingly large numbers of targets in a biological sample. In many embodiments of the invention, the larger the number of targets that are identifiable in a solution or mixture the better. The SELEX process allows for the selection of nucleic acid ligands without knowing what molecular target they bind to. For diagnostic and prognostic purposes, the specific targets can be almost irrelevant
15 as long as some pattern of target presence is indicative of a certain condition. By this process, it is likely that the presence of multiple targets, seemingly unrelated, would be determined to be diagnostic or prognostic of a given condition. This invention frees the investigator from having to determine which targets to detect within a given biological sample. Because SELEX can simultaneously identify ligands to huge numbers of epitopes within a complex
20 sample, a new diagnostic approach can be employed that does not rely on a previous knowledge of which targets are critical.

Thus, in certain aspects of the invention, the biochip may be comprised of literally thousands of nucleic acid ligands to indeterminate targets. In other embodiments, the targets for each attached nucleic acid ligand may be either predetermined based on the nature of the
25 SELEX protocol employed, or determined after the nucleic acid ligand was identified.

III. Production of the Nucleic Acid Ligand Biochip

The production of biochips on which nucleic acids are immobilized is well known in the art. The biochip may be a Langmuir-Bodgett film, functionalized glass, germanium,
30 silicon, PTFE, polystyrene, gallium arsenide, gold, silver, membrane, nylon, PVP, or any other material known in the art that is capable of having functional groups such as amino, carboxyl, Diels-Alder reactants, thiol or hydroxyl incorporated on its surface. Preferably,

these groups are then covalently attached to crosslinking agents, so that the subsequent attachment of the nucleic acid ligands and their interaction with target molecules will occur in solution without hindrance from the biochip. Typical crosslinking groups include ethylene glycol oligomer, diamines, and amino acids. Any suitable technique useful for immobilizing a nucleic acid ligand to a biochip is contemplated by this invention.

In one embodiment, one or more nucleic acid ligands will be attached to the support by photolithography using a photoreactive protecting group on a coupling agent. Such a technique is disclosed in McGall *et al.*, United States Patent No. 5,412,087. Thiolpropionate having a photochemically removable protecting group is covalently coupled to functional groups on the surface of the biochip. Light of the appropriate wavelength is then used to illuminate predefined regions of the surface, resulting in photodeprotection of the thiol group.

A mask will be used to ensure that photodeprotection only takes place at the desired sites or addresses. Nucleic acid ligands containing thiol reactive groups, such as maleimides, are then attached to the deprotected regions. The unbound nucleic acid ligand will then be washed away, and the process repeated at another location with another nucleic acid ligand. A similar method uses a 5'-nitroveratryl protected thymidine linked to an aminated biochip via a linkage to the 3'-hydroxyl group (Fodor *et al.* (1991) Science 251:767-773).

Photodeprotection of the thymidine derivative allows a phosphoramidite activated monomer (or oligomer) to react at this site. Other methods use a photoactivatable biotin derivative to spatially localize avidin binding. The avidin, by virtue of its ability to bind more than one biotin group at a time, will in turn be used as a means for spatially localizing a biotin-linked nucleic acid ligand to the biochip (Barrett *et al.*, United States Patent No. 5,252,743 and PCT 91/07807). In principle, the photodeprotection of a caged binding agent could be used for any ligand-receptor pair where one member of the pair is a small molecule capable of being protected by a photolabile group. Other examples of such ligand-receptor pairing include mannose and concanavalin A, cyclic AMP and anti-cAMP antibodies, and tetrahydrofolate and folate binding proteins (United States Patent No. 5,252,743).

In another embodiment, the regions of the biochip that come into contact with the nucleic acid ligand at each attachment photoactivation step are spatially restricted. This may be done by placing the support on a block containing channels through which the nucleic acid ligand will be pumped, with each channel giving the nucleic acid ligand access to only a small region of the biochip. This prevents accidental binding of nucleic acid ligand to non-

photoactivated regions. Furthermore, it will be used to permit the simultaneous attachment of several different nucleic acid ligands to the support. In this embodiment, a mask allows for the patterned illumination and consequent photoactivation of several regions of the biochip at the same time. If the area surrounding each photoactivated region is segregated from the neighboring region by the aforementioned channel, then different nucleic acid ligands will be delivered to these photoactivated regions by pumping each nucleic acid ligand through a different channel (Winkler *et al.*, United States Patent No. 5,384,261).

The photoactivated regions in the methods described above will be at least as small as 50mm^2 . It has been shown that $>250,000$ binding sites per square centimeter is easily achievable with visible light; the upper limit is determined only by the diffraction limit of light (Fodor *et al.* (1991) *Science* 251:767-773). Therefore, photoactivation using electromagnetic radiation of a shorter wavelength will be used to generate correspondingly denser binding arrays. If the biochip is transparent to the incident radiation it will be possible to simultaneously perform this process on a vertical stack of biochips, greatly increasing the efficiency of biochip production.

Alternatively, some form of template-stamping is contemplated, wherein a template containing the ordered array of nucleic acid ligands (and possibly manufactured as described above) will be used to deposit the same ordered array on multiple biochips.

In a further embodiment, the nucleic acid ligand array will be formed on the biochip by an "ink-jet" method, whereby the ligands are deposited by electro-mechanical dispensers at defined locations. An ink-jet dispenser capable of forming arrays of probes with a density approaching one thousand per square centimeter is described in Hayes *et al.*, United States Patent No. 5,658,802.

IV. Detection of Target Molecule Binding to Nucleic Acid Ligand Using Fluorescence Techniques

A. Generic Detection Techniques

In one embodiment, protein target molecules bound to nucleic acid ligands on the surface of the biochip will be detected by the addition of chemicals that non-specifically bind to all proteins but not to nucleic acids. More generally, such agents bind to proteins preferably over nucleic acids. Any fluorescent chemical that is known in the art to bind proteins non-specifically will be suitable. Suitable examples include the dyes Nanorange and

Cytoprobe, available from Molecular Probes, Inc.

In a preferred embodiment, specific detection of protein that is covalently (or non-covalently) coupled to immobilized aptamer can be achieved by taking advantage of the different reactivities of nucleic acid and protein functional groups. Nucleic acids have no
5 strong nucleophiles, whereas lysine and cysteine side-chains provide active nucleophiles to proteins. Lysine is a moderately abundant amino acid, comprising 4-6% of the side chains of most proteins. Cysteine varies considerably more in its abundance, and is often sequestered in disulfide bonds with other cysteine residues, rendering it less available for reaction.

Accordingly, the chemistry of protein modification through lysine residues is well-
10 developed. A large number of fluorophores or other tagging agents have been developed which react with lysine. The most common chemistries rely on the reaction of lysine with N-hydroxysuccinimide (NHS) esters, isothiocyanates, or in a variety of aldehyde reactions.

In another embodiment, target molecules bound to nucleic acid ligands will be detected on the biochip surface through the use of a sandwich assay. This method is well
15 known to those skilled in the art. A sandwich assay uses antibodies that recognize specific bound target molecules, preferably binding at a site distinct from that recognized by the nucleic acid ligand. In such sandwich assays, the antibodies may be fluorescently labeled, or the bound antibodies may themselves be detected by contacting the biochip with fluorescently labeled protein A, which binds all immunoglobulins. Alternatively, secondary antibodies
20 specific for the immunoglobulin subtype of the first (primary) antibody will be contacted with the biochip. The secondary antibodies may be fluorescently labeled, or they may be conjugated to a reporter enzyme, which enzyme catalyses the production of a detectable compound. Sandwich assays have the potential to greatly amplify the detectable signal, in this case by the ability of the secondary antibody to bind to multiple sites on the primary
25 antibody. All variations of the sandwich assay known in the art are contemplated in the subject invention.

In a related sandwich assay embodiment, the bound target molecule will be detected by the use of a second nucleic acid ligand, which binds to a site on the bound target distinct from that recognized by the biochip-bound nucleic acid ligand. As described in the paragraph
30 above, the second nucleic acid ligand may be fluorescently labeled, or it may be conjugated to biotin, allowing fluorescently labeled avidin, or an avidin conjugated reporter enzyme, to then bind to the bound second nucleic acid ligand. Alternatively, the first and second nucleic acid

ligands may be labeled in an appropriate manner so that they form an energy transfer pair, as described below in the section entitled "Detection Using an Oligonucleotide with Sequence Complementary to the Nucleic Acid Ligand."

In another embodiment, target molecule binding will be detected using a competition assay, well known to those skilled in the art. Following contacting of the biochip-bound nucleic acid ligands with the test mixture, a solution containing a predetermined amount of each target for which binding data is sought is added. These target molecules are fluorescently labeled by any of the ways known in the art in order to permit their detection. The labeled target molecules compete for binding to the immobilized nucleic acid ligand. An equilibrium will be established, and the amount of labeled molecule bound at each site will be used to calculate the amount of each target molecule contained within the original test mixture.

In another embodiment, protein enzymes bound to aptamers can be detected by an assay of enzyme activity.

B. Detection Using an Oligonucleotide with Sequence Complementary to the Nucleic Acid Ligand

In certain preferred embodiments (Figure 2), nucleic acid ligands (21) containing a constant sequence associated with the binding site for the target molecule will be localized to specific regions of a biochip (22). The synthesis of such nucleic acid ligands is described above in the section entitled "Obtaining Nucleic Acid Ligands For Use on a Biochip". The biochip-bound nucleic acid ligands will then be hybridized with an oligonucleotide (23) complementary in sequence to the constant region. Contacting this biochip with a test mixture will lead to displacement (24) of oligonucleotide from nucleic acid ligands that bind to their target molecule (25). In a further embodiment (Figure 3), a biochip (31) will be synthesized upon which the complementary oligonucleotide (32) is immobilized by any of the methods known in the art. The nucleic acid ligands (33) will then be deposited at specific locations on the biochip, whereupon they will become associated with the oligonucleotide by base pairing. The biochip will then be contacted with the test mixture. Target molecule binding (34) will lead to the disruption of base pairing between the nucleic acid ligand and the support bound oligonucleotide (35), and hence displacement of the nucleic acid ligand from the biochip will occur.

In the preceding embodiments, the displaced nucleic acid is labeled (26, 36) with fluorescein, tetramethylrhodamine, Texas Red, or any other fluorescent molecule known in the art, leading to a decrease in fluorescence intensity at the site of target molecule binding. The level of label detected at each address on the biochip will then vary inversely with the amount of target molecule in the mixture being assayed. Alternatively, the nucleic acid ligand and the oligonucleotide constitute an energy transfer pair. For example, one member of the pair will be labeled with tetramethylrhodamine and the other will be fluorescein labeled. The fluorescein-based fluorescence of such a complex is quenched when illuminated with blue light, as the green light emitted by the fluorescein will be absorbed by the tetramethylrhodamine group; the rhodamine-based fluorescence of this complex is not quenched. Separation of the two halves of this energy transfer pair occurs upon target molecule binding, and leads to a change in the emission profile at such sites on the biochip. The displacement of the tetramethylrhodamine labeled molecule will lead to the sudden appearance of fluorescein-based fluorescence at this site on the biochip, with the concomitant loss of rhodamine-based fluorescence. The simultaneous change in two different emission profiles will enable ratiometric imaging of each site to be performed, allowing sensitive measurement of target molecule binding. It is clear to those skilled in the art that any energy transfer pair can be used in this embodiment, providing that they have appropriately matched excitation and emission spectra.

In an alternative embodiment, the displaced nucleic acid is conjugated to one member of an affinity pair, such as biotin. A detectable molecule is then conjugated to the other member of the affinity pair, for example avidin. After the test mixture is applied to the biochip, the conjugated detectable molecule is added. The amount of detectable molecule at each site on the biochip will vary inversely with the amount of target molecule present in the test mixture. In another embodiment, the displaced nucleic acid will be biotin labeled, and can be detected by addition of fluorescently labeled avidin; the avidin itself will then be linked to another fluorescently labeled, biotin-conjugated compound. The biotin group on the displaced oligonucleotide can also be used to bind an avidin-linked reporter enzyme; the enzyme will then catalyze a reaction leading to the deposition of a detectable compound. Alternatively, the reporter enzyme will catalyze the production of an insoluble product that will locally quench the fluorescence of an intrinsically-fluorescent biochip. In another embodiment of the displacement assay, the displaced oligonucleotide will be labeled with an

immunologically-detectable probe, such as digoxigenin. The displaced oligonucleotide will then be bound by a first set of antibodies that specifically recognize the probe. These first antibodies will then be recognized and bound by a second set of antibodies that are fluorescently labeled or conjugated to a reporter enzyme. Many variations on these examples are well known to those skilled in the art.

In variations of the preceding embodiments, the nucleic acid ligand will not contain a constant sequence region as described above. In these embodiments, the oligonucleotide will have a sequence that is complementary to all, or part of, the nucleic acid ligand. Thus, each nucleic acid ligand will bind an oligonucleotide with a unique sequence. The oligonucleotides can be displaced from biochip-localized nucleic acid ligands as described above upon target binding. Alternatively, the oligonucleotides will be localized to specific locations on the biochip as described above, which will in turn result in the specific localization of nucleic acid ligands by complementary base-pairing to the oligonucleotides. Target molecule binding will displace the nucleic acid ligand from the biochip in this case, as described above. In each case, the oligonucleotide and/or the nucleic acid ligand will be labeled as described above.

In other embodiments, nucleic acid ligands will be localized to specific regions of the biochip. Following contacting with the test mixture, the biochip will then be contacted with a solution containing either (i) oligonucleotide with sequence complementary to the constant region of the nucleic acid ligand; or (ii) oligonucleotides with sequence complementary to all or part of each nucleic acid ligand, which ligand does not contain a constant sequence region as described above in this section. In these cases, binding of target will prevent the subsequent binding of oligonucleotide. Again, the oligonucleotide and the nucleic acid ligand can be labeled as described above in this section to monitor the binding of oligonucleotide.

C. Incorporation of Small Molecule Binding Sites into Nucleic Acid Ligands to Facilitate Target Molecule Binding

In another embodiment, SELEX will be performed using a pool of nucleic acids containing a binding site for a particular small molecule. An example of such a small molecule is the caffeine analogue theophylline. Single stranded nucleic acid ligands against this molecule form a double-stranded stem with a hairpin loop in which the 5' and 3' ends of the molecule are close to one another. This structure only forms in the presence of theophylline. In this embodiment, a candidate mixture of theophylline ligands will be

synthesized with random sequence in the hairpin loop region, and the candidates will then be passed over a solid support, preferably a column, to which theophylline has been attached. The candidate ligands will bind tightly to theophylline, and will become immobilized on the column. The mixture containing target molecules will be added to the column, and ligands that are eluted will be collected. This will select for ligands that bind their target molecules in such a way that the ligand will no longer bind to theophylline. Such ligands will be displaced because the adoption of the structure that binds the target molecule will disrupt the structure that binds the theophylline. The ligands will be refined in the standard ways described in the SELEX patent applications. A biochip (Figure 4) will then be fabricated (41) on which theophylline (42) is attached by any of the methods known in the art. One or more individual species of the nucleic acid ligands (43) will then be attached at defined locations on the biochip, where they bind tightly to the theophylline. Contacting of the test mixture with the biochip leads to the displacement (44) from the biochip of nucleic acid ligands that bind to their cognate target molecule (45). The displacement will be detected by any of the means detailed above (46). This technique will be used with any nucleic acid ligand that forms a hairpin-type structure similar to theophylline, or any other nucleic acid ligand that can be synthesized with additional random sequence, and will then bind to two different compounds in a mutually exclusive manner, such that the binding of one compound will displace the other.

In a related embodiment (Figure 5), nucleic acid ligands containing a binding site for a particular small molecule, such as theophylline, and a randomized segment will be synthesized as described in the above paragraph. The ligands (51) will also be labeled with both members of an energy transfer pair (52, 53), such that in the presence of the small molecule, these groups are close to one another, and fluorescence is quenched. The ligands will then be deposited at specific regions of the biochip (54), and the small molecule (55) will be added to the biochip. The ligands will adopt the structure that binds the small molecule, and fluorescence will be quenched. The test mixture will then be added to the biochip, and target molecules (56) will displace the small molecule from the appropriate nucleic acid ligands. In order to bind the target molecules, the nucleic acid ligands will undergo a conformational change in which the two halves of the energy transfer pair are no longer next to one another (57). This will result in a change in the fluorescence profile at each site on the biochip where a target molecule has been bound. This embodiment will also

be used for ligands that contain a binding for any small molecule, provided that such ligands undergo a conformational change upon displacement of the small molecule by the target molecule.

A different displacement scheme will use the target-molecule-dependent
5 displacement of a labeled single-stranded DNA-binding protein from a support bound nucleic acid ligand.

McGall *et al.*, *supra*, suggest a technique for simultaneously identifying multiple target nucleic acid sequences using multiple probes. In the method contemplated, a first set of labeled probes against specific targets is synthesized, with each probe containing an
10 additional sequence that is unique for that particular probe. These unique sequences are complementary to a second set of oligonucleotides immobilized on a biochip. The authors envision contacting the target and the first set of probes in solution, then adding the complexes formed to the biochip. The additional unique sequence region of each probe will localize that complex to a specific address on the biochip via its interaction with the second
15 probe bound at that site. Because there are methods known in the art that can be used to partition bound nucleic acid ligand from unbound, this technique can be applied to the instant invention. Specifically, nucleic acid ligands will be synthesized with an additional sequence that will be different for each species of nucleic acid ligand and will preferably be distant from the residues important for the specific binding interaction. The biochip will contain
20 oligonucleotides with sequence complementary to the unique region of each nucleic acid ligand species. Each nucleic acid ligand will also have a detectable group, such as a fluorophore and/or a means for linking the nucleic acid ligand to another detectable molecule as described above. Alternatively, the second set of biochip-localized nucleic acids and the nucleic acid ligands themselves can be labeled in such a way that they form an energy transfer
25 pair, as described above.

D. Detection of Binding Through a Signal-Amplifying Hybridization Cascade

Another series of embodiments of the instant invention will involve the use of a set of mutually-complementary nucleic acids. In all the methods, the nucleic acid ligand binds to a target molecule whereupon the nucleic acid ligand undergoes a conformational change that
30 allows other nucleic acids to hybridize thereto. The nucleic acids that hybridize to the target-bound nucleic acid ligand also undergo a conformational change during hybridization that similarly allows other nucleic acids to hybridize thereto. This chain reaction of

conformational change and hybridization will continue, forming an increasingly large intermolecular hybridization complex at each site on the biochip where a nucleic acid ligand binds to a target molecule. Any nucleic acid structure that undergoes a hybridization-promoting conformational change upon (i) binding to a target molecule, and/or (ii)

- 5 hybridizing to another nucleic acid, is suitable for use in this embodiment. The use of cascade hybridization is described in the commonly assigned application entitled "System for Amplifying Fluorescent Signal Through Hybridization Cascade," filed December 15, 1997, and specifically incorporated herein by reference.

The hybridizing nucleic acids will be labeled with a fluorescent group and a
10 quenching group at positions that are spatially adjacent only when the nucleic acid is not participating in a hybridization reaction. Therefore, the formation of the intermolecular complex will be accompanied by the generation of an increasing large fluorescent signal at each site on the biochip where a target molecule binds to a nucleic acid ligand. This signal can be detected by any of the fluorescence techniques known in the art.

- 15 In a preferred embodiment, a set of mutually-complementary stem-loop nucleic acids will be synthesized. A nucleic acid ligand will be designed with a stem-loop structure, in which the target molecule binding site is located in the loop region. Each said species of nucleic acid ligand will be immobilized at discrete locations on the biochip. The stem region will comprise two partially complementary "arms" of sequence A and B (Figure 6) that can
20 undergo limited pairing to form an imperfect intramolecular double helix (61). This nucleic acid ligand will undergo a structural change upon target molecule binding such that the stem region is completely disrupted (62). Three or more further sets of imperfect stem-loop nucleic acids will also be synthesized. The first further set will be identical to the biochip-bound nucleic acid ligand, but will not contain the target molecule binding site in the loop
25 region (63). The sequences of the stem regions of the latter two sets are represented as C'/A' (64) and B'/C (65), and are chosen so that they can bind perfectly to (i) one of the arms of the nucleic acid ligand stem (A' pairs perfectly with A, and B' pairs perfectly with B), and (ii) the arms of the second set can bind perfectly to the arms of the third set (C' pairs perfectly with C). The three sets will further comprise a fluorescent group (66) and a quenching group (67)
30 located at positions that are spatially adjacent only when the imperfect stem structure is formed. A biochip with the stem-loop nucleic acid ligands will be contacted with a test mixture, and target molecule binding will lead to the disruption of the stem region of said

nucleic acid ligands. Both sequences A and B will be available for base-pairing. The biochip will then be contacted with a solution of all three sets of nucleic acids. The arms of the stems of these latter nucleic acids will then hybridize to any nucleic acid ligand that has undergone a target-binding reaction (68). Upon binding to the nucleic acid ligand arms, the stem regions of the second and third set of nucleic acids will be similarly disrupted, and the unhybridized arms can then hybridize to their complementary sequences. This process is driven by the favorable free energy difference between imperfect and the perfect double helices, and will continue until one of the nucleic acids is depleted from the solution phase. At each hybridization step, another arm sequence becomes available for complementary base pairing, leading to the ultimate formation of a multimolecular complex of intermolecular double helices. Each hybridization step is accompanied by the spatial separation of the quenching group from the fluorescent group, resulting in a highly fluorescent signal (69) being generated at the site on the biochip where a single target molecule originally bound to a single nucleic acid ligand. In this embodiment, the original fluorescent signal is highly amplified by the cascade of hybridization.

E. Direct Binding of Target Molecules to Spectroscopically Detectable Nucleic Acid Ligands

In another embodiment, one or more spectroscopically detectable labeled nucleic acid ligands will be immobilized on biochips. The synthesis of such ligands is disclosed in Pittner *et al.*, United States Patent No. 5,641,629 and United States Patent No. 5,650,275, both of which are specifically incorporated herein by reference. The labels on such ligands undergo a detectable change in fluorescence intensity, fluorescence polarization or fluorescence lifetime upon binding of the nucleic acid ligand to its target molecule. Suitable labels include fluorescent labels (e.g. fluorescein, Texas Red), luminescent labels (e.g. luciferin, acridinium esters), energy transfer labels (e.g. fluorescein and tetramethylrhodamine), and near IR labels (e.g. dicyanines, La Jolla Blue dye). Binding of the target molecule to the labeled ligand will be detected by measuring any change in fluorescence. These include, but are not limited to, changes in fluorescence polarization, fluorescence anisotropy, fluorescence intensity, and fluorescence lifetime. These measurements will be made continuously, or in a dynamic manner. Locations on the biochip where a difference is detectable will then be known to have

bound target molecules, allowing the quantification of each target molecule in the test mixture.

In a preferred embodiment, nucleic acid ligands bound to the biochip will be labeled with one or more phosphorescent groups. These groups will be incorporated into the nucleic acid ligand such that at least some of them are within the binding site of the target molecule. The phosphorescent groups will be chosen from those known in the art so that they have an emission half life which is longer by a predetermined amount than the half life of non-specific binding of an inappropriate target molecule to a nucleic acid ligand. The medium in which the biochip is incubated will contain a predetermined amount of a quenching agent that can effectively quench the phosphorescence. When target molecule binds to a nucleic acid ligand in a specific manner, then the phosphorescent groups will be protected from the quenching agents. If the biochip is then illuminated with light of the appropriate wavelength, the phosphorescent groups of nucleic acid ligands with specifically bound target molecules will phosphoresce, and hence light will be detected at sites on the biochip where ligand is bound.

The phosphorescence of nucleic acid ligands that are unbound will be quenched, and so no light will be detected at such sites on the biochip. The phosphorescence of nucleic acid ligands that bind an inappropriate, non-cognate target molecule will also be quenched, as the half life for the formation of these complexes will be much shorter than the emission half life of the phosphorescence groups. In other words, the individual phosphorescent groups in a non-specific complex will be many more times likely to encounter a quenching group in the solvent prior to photon emission than will those same groups in a specific complex. Any suitable phosphorescent group with an emission half life greater than the half life of formation of a specific nucleic acid ligand-target complex is contemplated in the present invention. If the detection of phosphorescence is delayed by a predetermined amount of time following excitation illumination, then the phosphorescence signal can be distinguished from the background fluorescence signals, as these latter signals have a much shorter emission half life. This delay will also further enhance the specificity of detection, as only truly tightly bound nucleic acid ligands will be protected from quenching. Furthermore, a series of phosphorescence images of the biochip will be obtained, with optional brief washing of the biochip between each exposure; the resulting series of images will then be integrated. This will enable non-specific signal to be further distinguished from non-specific signal, as the specific binding will persist between exposures, whereas the non-specific binding will not.

In another embodiment, the technique described in the preceding paragraph will be carried out using fluorescence groups on the nucleic acid ligands, rather than phosphorescence groups.

F. Detection of Changes in Double-Helicity Accompanying Target Binding

5 In another embodiment, target molecule binding will be assessed by monitoring changes in the degree of double-strandedness of each nucleic acid ligand. It is known that nucleic acid ligands undergo structural changes upon binding to target, such as the formation, or expansion, of double stranded regions. In the instant invention, these changes will be detected by adding a fluorescent intercalating dye, such as ethidium bromide, to the biochip,
10 and measuring fluorescence levels at each location on the biochip in the presence and absence of the test mixture. A similar technique is suggested in Lockhart *et al.* (United States Patent No. 5,556,752) for determining oligonucleotide probe hybridization to a target nucleic acid sequence.

G. Detection Through the use of Interferometry

15 In another embodiment, target molecule binding will be detected by the use of an interferometric sensing system. A suitable system is described in Lin *et al.* (1997) Science 278: 840-842. Nucleic acid ligands will be attached to a microporous biochip surface. Illumination of this surface with white light produces an interference pattern. This results from light being reflected from the top and bottom of the porous biochip surface. Interaction
20 of a target molecule with a nucleic acid ligand locally alters the refractive index of the biochip surface, and this in turn locally alters the wavelength of the interference fringe pattern. This can be measured by, for example, a charge coupled device camera.

H. Detection of Covalently Bound Target Molecules

In another embodiment, methods known in the art that allow for the synthesis of
25 nucleic acid ligands containing one or more photoreactive groups, such as iodouridine, will be used. These ligands are capable of binding to their target, and then becoming covalently attached to the target upon photoactivation of the reactive group with light of the appropriate wavelength.

In a most preferred embodiment, these ligands are developed by photoselection of
30 nucleic acids (photoSELEX) (see United States Patent Number 5,763,177) and are capable of binding to a target. Upon photolysis the ligands become covalently attached to the target. The addition of a covalent photocrosslink gives a secondary specificity, which is not normally

seen in diagnostics. In addition to binding, the formation of a covalent crosslink can only occur between the protein and the aptamer if a chemically reactive electron donating amino acid is in proximity to the photoaffinity label. This specificity is achieved by selection of the aptamer based on the ability to photocrosslink to the specific target protein if and only if a crosslinkable amino acid is in an orientation that is amenable to crosslink formation.

Therefore, the aptamer will not crosslink to a protein that it was not specifically selected to crosslink to even though it may be associated in a non-specific manner. The very covalent nature of the crosslink also adds to specificity in that it allows the crosslinked complex to be washed under stringent conditions that would normally disrupt an affinity based detection.

Stringent washing can therefore be used to decrease the noise in detection and thereby increase the ratio of signal to noise.

An array of photoreactive aptamers will be attached to biochip or other surface, in a spatially defined manner, and then contacted with the test mixture. The chip can be directly irradiated, or gently washed before irradiation to remove the un-associated proteins. In effect, the irradiation will covalently attach only the correct protein to the correct photoactivatable aptamer presented at a defined area of a matrix laid out on the surface of the chip. The protein, covalently bound to the aptamer can be detected by sandwich assay, or fluorescent or radioactive protein dye as described in the above section entitled "Generic Detection Techniques". The addition of covalent attachment provides that the detection of the protein can be achieved via chemical modification of reactive groups that are unique to the protein and not to the aptamer or chip. In addition, covalent attachment allows for a myriad of protein detection methods that are not limited by dissociation of the complex, such as organic solvents, temperature, denaturant or other methods that generally dissociate a non-covalent association.

Alternatively, the covalently associated complexes on the biochip will be contacted with oligonucleotides complementary to all, or part of, the sequence of the nucleic acid ligand. Nucleic acid ligands that are covalently bound to target will not be able to hybridize to the complementary oligonucleotide. The complementary oligonucleotides will be labeled by any of the methods known in the art, as described above, to facilitate their detection.

V. Detection of Target Molecule Binding Through Methods That Do Not Involve Fluorescence

Although preferred embodiments utilize fluorescent and phosphorescent detection techniques for determining target molecule binding, there are other methods known in the art that have utility in this application.

A. Chemical Field Effect Transistors

Chemical field effect transistor (CHEM-FET) technology exploits the local change in chemical potential that is created upon the binding of target molecule to its ligand. In this technology, an insulative silica "gate" is placed between two n-type semiconductors, forming a biochip. Current will flow from one semiconductor to the other when a conducting channel is formed in the gate and a potential difference is applied. Such channels will be opened when an ionic species binds to the silica gate (Schenk *et al.* United States Patent No. 4,238,757). In another method (Lowe *et al.*, United States Patent No. 4,562,157), ligands are bound to discrete regions of one of the semiconductors via photoactivation of derivatizing groups. The biochip is then contacted with a mixture containing target molecules. Binding of a target molecule to a ligand leads to a net loss or gain of ions at that location of the biochip. The ions locally alter the conductance at this location, which in turn leads to a change in the drain current in this area of the biochip. If the biochip is configured in such a way that current drains will be measured in discrete locations on the biochip (multigated CHEM-FET), then spatial and quantitative assessment of target binding will be achieved. Advances in the art should permit the scaling up of this technology to independently and accurately measure thousands of spatially discrete changes in drain current.

Another bioelectric change that can be measured using CHEM-FET is the photo-induced electron transfer which occurs in double-stranded DNA (Murphy *et al.* (1993) Science 262:1025-1029). As mentioned above, the degree of double-strandedness of each nucleic acid ligand may change when a target molecule is bound. Changes in the extent of double-helicity will lead to localized changes in drain currents in a CHEM-FET biochip that is being illuminated. If the CHEM-FET biochip is read before and after contact with the target mixture, then detecting these differences will reveal the sites and extent of target molecule binding.

B. Detection Through Surface Plasmon Resonance

In a preferred embodiment, target molecule binding will be detected through surface plasmon resonance (SPR). In this technique, nucleic acid ligand is immobilized on a gold or silver film on the surface of a prism; the metal film is then incubated in the appropriate liquid medium. Therefore, the metal film is at the prism-liquid interface. Light is directed through the prism towards the medium, and above a critical angle, total internal reflection of the light occurs. Above this critical angle, an evanescent wave extends into the medium by a distance that is approximately equal to the wavelength of the incident light. The evanescent wave excites free oscillating electrons, termed surface plasmons, in the metal film, and causes them to resonate. Energy is absorbed from the evanescent wave by the electrons during this process, thereby reducing the intensity of the internally reflected light. The angle at which total internal reflection, and hence resonance, occurs is exquisitely sensitive to changes in the refractive index of the medium immediately adjacent to the metal film. When a target molecule binds to a nucleic acid ligand on the surface of the film, the refractive index at this site changes, and the angle needed to cause resonance changes also. Thus in order to detect target molecule binding, a detector system is arranged in which the angle of incident light is varied, and the intensity of the reflected light is measured. Resonance occurs when the intensity of the reflected light is at a minimum. Measuring the change in angle of incident light needed to bring about resonance at specific sites on the film in the presence of a test mixture can then yield information about where a binding reaction has occurred on the surface of the film. A device for measuring SPR called BIAcore7 is commercially available from Pharmacia Biosensors.

C. Detection Through the Use of Mass Spectroscopy

In another embodiment, the formation of nucleic acid ligand-target complex will be detected by mass spectroscopy. The surface of the biochip will be irradiated in a spatially restricted and sequential way using a laser that is capable of ionizing the biological material on the biochip. The mass of the ionization products will be detected by mass spectroscopy, and comparison with the mass of ionization products of the same unbound ligands will reveal where target is bound. This technique is known in the art as Matrix Absorption/Laser Desorption and Ionization (MALDI) Time of Flight Mass Spectroscopy. The nucleic acid ligands and the targets in this embodiment can be covalently associated through the use of

photoactivatable crosslinking groups on the nucleic acid ligand, as described above in the section entitled "Detection of Covalently Bound Target Molecules".

D. Detection Through Atomic Force Microscopy (AFM) and Scanning-Tunneling Microscopy (STM)

5 These related methods are well known in the art as techniques useful for describing the topology of surfaces at the nanometer level. Hence, advances in these techniques will make them suitable for detecting sites on a biochip where target molecule has been bound by a nucleic acid ligand.

Atomic force microscopy (AFM) uses a non-metallic probe which is scanned over the
10 surface of interest, in this case a biochip. The probe is moved close to the surface so that the probe is subject to electron-repulsive interactions with the material bound to the surface. Repulsion leads to the deflection of a cantilever upon which the probe is mounted, and this deflection is measured by a laser-photodiode detection system. The surface under
examination is mounted on a stage, which stage is coupled to the deflection detection system
15 by a computer. When the probe is deflected, the stage is lowered, allowing the probe to trace out a "contour map" of electron density for the surface. Using this technique, a reference map for a nucleic acid biochip in a buffer will be prepared. This will be compared with a map obtained from a nucleic acid biochip that has been incubated with a test mixture. Comparison of the two maps will allow detection of sites on the biochip where target molecule has bound.

20 Scanning tunneling microscopy (STM) uses a metallic probe which is scanned over a surface of interest. When the probe approaches the material bound to the surface, electrons can "tunnel" between the probe and the material, and the resulting current can be detected. The probe is scanned over the surface, and the vertical position of the probe is constantly varied to permit tunneling. This, as in AFM, gives a map of electron density, which map will
25 be used as described in the above paragraph to detect target molecule binding on a nucleic acid ligand biochip.

VI. Examples

A. Example One

30 Nucleic acid ligand GB41 was isolated from a SELEX experiment against the U251 glioma cell line, as described in United States Patent Application No. 08/434,425, filed 5/3/95, entitled "Tissue SELEX." Here, the nucleic acid ligand bears a 5' biotin and is

immobilized to a streptavidin coated carboxymethyl dextran biochip surface (BIAcore 2000). The proteins are injected across flowcells containing GB41 or a version of GB41 in which the nucleotide sequence is scrambled. The scrambled sequence provides a test of binding specificity for the nucleic acid ligand. Specific binding was detected to full-length tenascin and to a bacterially expressed protein representing fibronectin type III repeats 3-5, which comprises 12% of the mass of full-length tenascin. These proteins did not bind to the scrambled sequence oligonucleotide. The slow dissociation of full-length tenascin, a hexamer, may result from multivalent interactions on the surface. Experiments established the association and dissociation rate constants for this protein-nucleic acid ligand interaction.

10 The association phase (0-125 sec) was linear due to the large size (1.2 million dalton) of tenascin, which causes slow diffusion into the dextran matrix (mass transport-limited binding). The slow dissociation (125-300 sec) was perhaps due to multivalent interactions that could form between the hexameric protein and the dextran-bound nucleic acid ligand.

B. Example Two

15 An NHS and an aldehyde reagent have been tested for their reactivities with proteins relative to nucleic acids. Fluorescein-NHS (Molecular Probes) was added to human serum albumin or alpha-1 HS glycoprotein (two abundant plasma proteins) at 5000-fold molar excess. A 42-mer DNA was also added at 0-1000 -fold molar excess relative to the protein. The reaction was allowed to proceed for 30min at room temperature at pH8. The protein, DNA and unreacted fluorophore were resolved by gel electrophoresis, and the relative intensities of each product were determined by scanning and quantitation on a Molecular Dynamics FluorImager. Fluorescein-NHS was 2.1×10^4 -fold more reactive with serum albumin than with DNA on a mol:mol basis, and 4400-fold more reactive on a mass basis. Alpha-1 HS glycoprotein was 8000-fold more reactive than DNA on a mol basis, and 3700-

25 fold more reactive on a mass basis.

A similar experiment has been completed for the reaction of human serum albumin with AttoTag CBQCA (Molecular Probes), an aldehyde coupling reagent which reacts with primary amines and cyanate to form a fluorescent benzoisindole product. In this case, the protein reacted readily with albumin, but no reaction with DNA was detectable at a 1000-fold excess of DNA over albumin. Albumin was calculated to be at least 3×10^4 -fold more

30 reactive to this reagent than is DNA.

What is claimed is:

1. A diagnostic biochip for detection of a target molecule in a test mixture, the biochip comprising a solid support, said support comprising a plurality of spatially defined
5 addresses, each said address having at least one copy of a single species of nucleic acid ligand attached thereto, each said species of nucleic acid ligand having specific affinity for one of said target molecules suspected of being contained in said test mixture, and each said species of nucleic acid ligand binding to said target molecule through non-Watson-Crick interactions.
- 10 2. A method for making a biochip, the method comprising:
 - I. identifying nucleic acid ligands to a target by the method:
 - (a) preparing a candidate mixture of nucleic acid sequences;
 - (b) contacting said candidate mixture of nucleic acids with a biological
15 solution from an individual with a known medical condition, wherein nucleic acids having an increased affinity to target molecules contained within said biological solution relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
 - (c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;
 - (d) amplifying the increased affinity nucleic acids to yield a mixture of
20 nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to said target molecules, whereby nucleic acid ligands of said target molecules may be identified;
 - (e) repeating steps b), c) and d) until said nucleic acid ligands possess the desired affinity for said target molecules contained within said biological solution;
 - 25 II. attaching said nucleic acids ligands to spatially discrete locations on a solid support.
- 30 3. A method for diagnosing a medical condition, the method comprising:
 - (a) identifying nucleic acid ligands to target molecules contained within a biological mixture obtained from an individual with said medical condition;

(b) binding said nucleic acid ligands to spatially discrete locations on a solid support;

(c) determining the pattern of binding of said target molecules contained within biological mixtures obtained from individuals with and without said medical condition;

(d) determining the pattern of binding of said target molecules contained within a biological mixture obtained from an individual requiring a diagnostic test for said medical condition;

(e) comparing the pattern of binding in (d) with the patterns of binding in (c);

whereby a diagnosis of said medical condition can be made if the binding pattern in (d) is similar to the binding pattern obtained from the biological mixture of an individual known to have said medical condition.

4. A method for detecting a target molecule in a test mixture, the method comprising:

(a) preparing a biochip, the biochip comprising a solid support, said support comprising a plurality of spatially defined addresses, each said address having at least one copy of a single species of nucleic acid ligand attached thereto, each said species of nucleic acid ligand having specific affinity for one of said target molecules suspected of being contained in said test mixture, and each said species of nucleic acid ligand binding to said target molecule through non-Watson-Crick interactions;

(b) contacting said biochip with said test mixture;

(c) measuring the amount of said target molecule bound to said biochip at one or more of said addresses, said addresses being known to be capable of binding said target molecule;

whereby said target molecule binds to one or more of said species of nucleic acid ligand; whereby said species of nucleic acid ligand is localised to one or more of said addresses on said biochip;

whereby measuring the amount of said target molecule bound at said addresses reveals the concentration of said target molecule in said test mixture.




Fig. 1

2/6




Fig. 2

3/6




Fig. 3

4/6




Fig. 4

5/6




Fig. 5

6/6




Fig. 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26515

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12Q 1/68; C12P 19/34; C07H 21/04

US CL :435/6, 91.1,91.2; 536/24.31,24.32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.1,91.2; 536/24.31,24.32

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,688,935 A (STEPHENS et al) 18 November 1997 (11/18/97), see entire document esp. columns 4-15.	1-4
Y	US 5,510,270 A (FODOR et al) 23 April 1996 (04/23/96), see entire document esp. abstract.	1-4
Y	LIPSHUTZ, L.J. et al Using Oligonucleotide Probe Arrays to Access Genetic Diversity. Biotechniques. 1995, Vol. 19, No. 3, pages 442-447, see entire document.	1-4
Y	US 5,412,087 A (MCGALL et al) 02 May 1995 (05/02/95), see entire document esp. abstract.	1-4

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 MARCH 1999

Date of mailing of the international search report

13 APR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JEFFREY SIEW

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26515

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,E	US 5,861,254 A (SCHNEIDER et al) 19 January 1999 (01/19/99), see entire document.	1-4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/26515

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN, WPIDS, BIOSIS, MEDLINE, CANCERLIT, BIOTECHDS, LIFESCI, CAPLUS, EMBASE
search terms: sclex, nucleic acid ligand, chip, array, amplification, probe, oligonucleotide